Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The table below provides a snapshot of their recent ratings, ...
WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics is waving goodbye to 66 employees—equivalent to 30% of its workforce. (iStock/Getty Images Plus) TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) ...
WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
Data from ALLOHA™ Phase 1 heme trial to be presented at the 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Made the strategic decision to prioritize clinical development of ...
(MENAFN- GlobeNewsWire - Nasdaq) Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHATM Phase 1 heme trial to be presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results